Charles River Laboratories International Aktie
WKN: 939391 / ISIN: US1598641074
09.05.2024 13:34:14
|
Charles River Laboratories Reaffirms FY24 Outlook; Q1 Results Top Estimates
(RTTNews) - While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) reaffirmed its adjusted earnings, revenue growth and organic revenue growth guidance range for the full-year 2024.
For fiscal 2024, the company now projects earnings in the range of $7.60 to $8.10 per share and adjusted earnings in the range of $10.90 to $11.40 per share on revenues growth of 1.0 to 4.0 percent, with organic revenues growth of flat to 3.0 percent.
Previously, the company expected earnings in the range of $7.90 to $8.40 per share and adjusted earnings in the range of $10.90 to $11.40 per share on revenues growth of 1.0 to 4.0 percent, with organic revenues growth of flat to 3.0 percent.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $11.02 per share on revenue growth of 2.13 percent to $4.22 billion for the year. Analysts' estimates typically exclude special items.
For the first quarter, the company reported the net income attributable to common shareholders of $67.33 million or $1.30 per share, lower than $103.13 million or $2.01 per share in the prior-year quarter.
Excluding items, adjusted earnings for the quarter was $2.27 per share, compared to $2.78 per share in the year-ago quarter.
Total revenue for the quarter decreased 1.7 percent to $1.01 billion from $1.03 billion in the same quarter last year. Organic revenue declined 3.3 percent.
The Street was looking for earnings of $2.07 per share on revenues of $992.27 million for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Charles River Laboratories International Inc.mehr Nachrichten
22.04.25 |
Erste Schätzungen: Charles River Laboratories International präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) | |
21.04.25 |
S&P 500-Wert Charles River Laboratories International-Aktie: So viel Verlust hätte ein Charles River Laboratories International-Investment von vor 5 Jahren eingebracht (finanzen.at) | |
21.04.25 |
Schwacher Handel in New York: S&P 500 zum Start leichter (finanzen.at) | |
14.04.25 |
Börse New York: S&P 500 letztendlich in Grün (finanzen.at) | |
14.04.25 |
Starker Wochentag in New York: S&P 500 notiert am Nachmittag im Plus (finanzen.at) | |
14.04.25 |
NYSE-Handel: S&P 500 mittags stärker (finanzen.at) | |
14.04.25 |
S&P 500-Titel Charles River Laboratories International-Aktie: So viel Verlust hätte eine Charles River Laboratories International-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
11.04.25 |
NYSE-Handel: S&P 500 verbucht am Mittag Gewinne (finanzen.at) |
Analysen zu Charles River Laboratories International Inc.mehr Analysen
Aktien in diesem Artikel
Charles River Laboratories International Inc. | 100,80 | -0,30% |
|